0      0


JL1126ES - JL1126ES: Patient-reported outcomes (PROs) in primary advanced or recurrent endometrial cancer (pA/rEC) for patients (pts) treated with dostarlimab plus carboplatin/paclitaxel (CP) as compared to CP in the ENGOT-EN6/GOG3031/RUBY trial


‐ Oct 23, 2023 10:00pm

Full author listing

Mansoor Raza Mirza, MD1; Matthew A. Powell, MD2; Caroline Lundgren3; Vladyslav Sukhin4; Bhavana Pothuri, MD5; Lucy Gilbert, MD6; Sarah E. Gill, MD7; Graziana Ronzino8; Nicole Nevadunsky, MD9; Stefan Kommoss10; Lyndsay Willmott, MD11; Ingrid Boere, MD12; Cara Mathews, MD13; Joseph Buscema, MD14; Michael G. Teneriello, MD, FACOG15; Mark S. Shahin, MD16; Oren Meyers, PhD17; Jamie Garside18; Robert L. Coleman, MD19; Brian Slomovitz, MD20

1Rigshospitalet, Copenhagen University Hospital, Denmark, Nordic Society of Gynaecologic Oncology–Clinical Trial Unit, Copenhagen, Denmark; 2Washington University, St Louis, MO; 3Karolinska University Hospital, Stockholm, Sweden; 4Grigoriev Institute for Medical Radiology and Oncology, National Academy of Medical Science of Ukraine, Kharkov, Ukraine; 5Gynecologic Oncology Group and Department of Obstetrics/Gynecology, Perlmutter Cancer Center, NYU Langone Health, New York, NY; 6Division of Gynecologic Oncology, McGill University Health Centre, Montreal, QC, Canada; 7Nancy N. and J.C. Lewis Cancer and Research Pavilion, Savannah, GA; 8Department of Oncology, Ospedale “Vito Fazzi”, Lecce, Italy; 9Albert Einstein College of Medicine, New York, NY; 10Department of Women’s Health, Tübingen University Hospital, Tübingen, Germany; 11Arizona Center for Cancer Care, Phoenix, AZ; 12Department of Medical Oncology, Erasmus MC, Rotterdam, the Netherlands; 13Legorret 14Arizona Oncology Associates, Tucson, AZ; 15US Oncology Research, The Woodlands, TX; 16Sidney Kimmel Medical College of Thomas Jefferson University, Jefferson Abington Hospital, Abington, PA; 17GSK, Collegeville, PA; 18GSK, London, UK; 19Texas Oncology, Sarah Cannon Research Institute, TN; 20Mount Sinai Medical Center, Miami Beach, FL